<DOC>
	<DOCNO>NCT02498808</DOCNO>
	<brief_summary>Neutrophils emerge key immune cell initiation perpetuation immune response autoimmune disease . They display marked abnormality phenotype function various autoimmune disease , include systemic vasculitis , systemic lupus erythematosus ( SLE ) rheumatoid arthritis ( RA ) . These neutrophil characterise extended life span , increase capacity produce reactive oxygen specie , active gene expression release extracellular trap . Consequently , need good understand neutrophil phenotype function condition , well identify molecule capable specifically manipulate neutrophil function . The investigator recently discover interferon lambda ( IFN-λs ) , also know interleukin 28 ( IL28 ) interleukin 29 ( IL29 ) , class II cytokines previously study anti-viral biological function , specifically suppress neutrophil infiltration interleukin-1β production thereby , halt reverse development collagen induce arthritis ( CIA ) . The investigator propose investigate cellular molecular mechanism behind suppression examine translational potential investigator ' find examine IFN-λ receptor expression function neutrophil isolate blood healthy donor rheumatic patient ( early rheumatoid arthritis vasculitis ) .</brief_summary>
	<brief_title>Interferon-lambda : Novel Biologics Controlling Neutrophil-mediated Pathology Rheumatic Diseases ?</brief_title>
	<detailed_description>Expression Interferon lambda receptor 1 ( IFNLR1 ) /interleukin 28 Receptor Alpha ( IL28RA ) human neutrophil . Neutrophils isolate freshly draw human blood subsequent removal red blood cell dextran and/or magnetic-activated cell sort ( MACS ) . The investigator ' preliminary result show neutrophils isolate blood healthy donor express high level IL28RA messenger Ribonucleic Acid ( mRNA ) compare Cluster Differentiation-14 ( CD14 ) negative CD14 positive lymphocyte . To good understand relative spread IL28RA mRNA level due human heterogeneity , investigator compare level IL28RA expression neutrophil isolate blood 20 healthy donor . The investigator examine whether treatment human neutrophils ex vivo recombinant human IL29 ( Bristol- Meyers Squibb , BMS ) induce Signal Transducer Activators Transcription 1 ( STAT1 ) signalling . The investigator also test newly generate antibody human IL28RA show specificity IL28RA detection cell line , neutrophil isolated blood . Expression IFNLR1/IL28RA neutrophils isolate blood rheumatic patient . The investigator compare level IL28RA expression neutrophil isolate blood ( 1 ) 15 patient early phase rheumatoid arthritis ( RA ) naïve biologic therapeutic intervention ; ( 2 ) 15 vasculitis patient giant cell arteritis ( GCA ) ( within one week commence high dose glucocorticoid ) ( 3 ) 15 vasculitis patient granulomatosis polyangitis ( GPA ; Wegener 's ) presentation relapse , prior initiation immunosuppressive therapy either cyclophosphamide rituximab . All patient undergo standardise assessment disease activity damage , i.e . Birmingham Vasculitis Activity Score version 3.0 ( BVAS 3.0 ) Vasculitis Damage Index version 1.0 ( VDI ) vasculitis disease activity score 28 joint ( DAS-28 ) RA . This allow investigator predict whether rheumatic patient likely respond IL29 treatment . Functional characterisation human neutrophil treat IL29 . The investigator conduct selective evaluation expression adhesion molecule , migratory response functional property human neutrophil treat IL29 ex vivo . These select activity examine IL29 treat neutrophil blood healthy donor , without stimulation lipopolysaccharide ( LPS ) , phorbol myristate acetate ( PMA ) serum RA vasculitis patient . The investigator assess impact IL29 treatment neutrophil isolate blood patient RA vasculitis .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Collagen Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Healthy volunteer Recent diagnosis rheumatoid arthritis within 1 month New diagnosis giant cell arteritis within 1 month New diagnosis antineutrophil cytoplasm antibody associate vasculitis within 1 month Flare antineutrophil cytoplasm antibody associate vasculitis within one month Unable provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Interferon lambda</keyword>
	<keyword>Interleukin-29</keyword>
	<keyword>Neutrophil</keyword>
</DOC>